SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices climb amid reported attacks on Middle East shipping and energy infrastructure, raising fears of supply disruptions around the Strait of Hormuz. Traders are split between betting that geopolitical risks will keep oil elevated and expecting prices to retreat if shipping conditions improve or diplomacy eases tensions.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Concerns over CoreWeaves debt-funded data-center expansion and access to financing dominate the discussion, amplified by HSBCs bearish assessment of debt costs and AI-demand risks. Bears warn of further downside and question insider selling, while bulls point to contracted demand, Goldmans more positive view and ARKs buying as reasons the selloff may be overdone.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is under pressure as traders connect the stocks slide to weakening confidence in Trump ahead of the midterms, alongside concerns about Truth Socials limited business scale, losses, and crypto exposure. Discussion is overwhelmingly bearish, though some traders see a possible short-term bounce and point to the pending TAE fusion deal as a potential diversification opportunity.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

Barclays downgrade to Underweight has intensified selling, with traders focused on commercial execution risk and the lack of a definitive TVAENTRA1 agreement for NuScales proposed deployment. Bears see delayed contracts as evidence the business case is faltering, while some bulls view the selloff as overdone and are waiting for concrete project progress.

USA Rare Earth, Inc. is a domestic supplier of rare earth magnets and heavy rare earth elements. It develops a vertically integrated domestic supply chain for rare earth element magnet production, with a facility in Stillwater and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

A prolonged selloff has focused attention on USAR, with traders pointing to dilution concerns, heavy spending before production scales, and frustration with managements limited communication after the CEO transition. Bulls cite the companys strategic role in a U.S. rare-earth supply chain and government backing, while bears question execution and near-term economics.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforces agreement to acquire customer-engagement platform Braze is drawing attention, with traders weighing the deals potential to strengthen Marketing Cloud and its AI strategy against concerns about the cost and pressure on CRM shares. Some also frame the deal as part of Salesforces broader push to expand its enterprise software offerings.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings and revenue beat expectations, and the company authorized a large share buyback, but shares fell as traders focused on a narrowed full-year profit outlook that offered no improvement at its midpoint and weaker U.S. sales. Some see the buyback and cash flow as supportive, while others argue the cautious outlook outweighed the strong quarter.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

CEO Angelos Stergious 15th-anniversary LinkedIn post about the companys next chapter with GPS and SLS009 has fueled speculation about a potential buyout and imminent clinical news, though neither was confirmed. Discussion also centers on the REGAL Phase 3 trials final analysis, triggered at 80 deaths versus 78 last disclosed: bulls view the extended wait as potentially encouraging, while skeptics say the blinded trials timing cannot establish efficacy and question managements communication.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTXs quarterly results topped expectations and management raised its full-year outlook, with traders pointing to strong aerospace and defense demand and a record backlog. The upbeat results have drawn bullish reactions, though some traders are frustrated that the share price has not responded more strongly.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are under heavy selling pressure amid repeated lockup expirations and reported insider sales, with traders also citing a lower analyst price target and concerns about OpenAI customer concentration and competition. Bearish calls for further declines contrast with bulls arguing the selloff is overdone and the companys AI-chip technology has long-term potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Boston Scientific (BSX) Rises Higher Than Market: Key Facts

Boston Scientific (BSX) closed at $44.14 in the latest trading session, marking a +2.65% move from the prior day.

Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance?

J&J's shares fell 5.8% despite an earnings beat and raised guidance, as MedTech weakness, drug sales shortfalls and acquisition costs weighed on results.

Why Boston Scientific (BSX) Outpaced the Stock Market Today

Boston Scientific (BSX) reached $42.73 at the closing of the latest trading day, reflecting a +1.64% change compared to its last close.

Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors

Boston Scientific (BSX) concluded the recent trading session at $42.04, signifying a +1.11% move from its prior day's close.

Boston Scientific Corporation (BSX) is Attracting Investor Attention: Here is What You Should Know  

Recently, Zacks.com users have been paying close attention to Boston Scientific (BSX). This makes it worthwhile to examine what the stock has in store.

Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer

Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating OfficerPR NewswireMARLBOROUGH, Mass., Oct. 7, 2026New operating structure designed to increase efficiency...

Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown?

J&J's MedTech faces Abiomed and competitive pressures, but Vision, Orthopedics and Surgery could drive a stronger second half.

Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Boston Scientific (BSX) closed at $42.6, marking a -1.46% move from the previous day.

If You Invested $1000 In Boston Scientific Stock 15 Years Ago, You Would Have This Much Today

Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.13% on an annualized basis producing an average annual return of 14.35%. Currently, Boston Scientific has a market capitalization ofread more...

Can ISRG Offset China Weakness With Expansion in India and Japan?

Intuitive Surgical sees strong growth in India and improving conditions in Japan helping offset China headwinds as international da Vinci procedures rise 20%.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific Says Cyberattack Will Impact 2026 Results — Says It Is ‘Unlikely’ To Meet Net Sales Growth, EPS Guidance Ranges

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The company expects to recover some impacted revenue as it works through order backlogs, but said the full financial impact remains uncertain.</li><li>Boston Scientific has resumed certain operations, but the timeline for a full operational recovery is not yet known.</li><li>The firm previously expected third-quarter sales to grow between 3% and 5% of its Q3 2025 sales of $5.07 billion.</li></ul>Boston Scientific (BSX) said a cyberattack that disrupted its global operations last month is expected to materially impact its third-quarter and full-year 2026 results, making it unlikely to meet its previously forecast net sales growth and adjusted earnings per share (EPS) guidance ranges.The medical-device maker first <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000885725/000088572526000056/bsx-20260826.htm">identified</a> the incident on August 25. Unauthorized activity caused a network outage that limited access to operating systems and business applications, disrupting manufacturing and the processing and shipment of customer orders.At the time of writing, <a href="https://stocktwits.com/symbol/BSX">BSX shares</a> were trading over 5% lower, having declined around 9% since reporting the incident.<h2 class="st-heading-2">BSX To Miss Sales, Profit Targets</h2>Boston Scientific previously expected third-quarter (Q3) 2025 sales to grow between 3% and 5% from its Q3 2025 sales of $5.07 billion. Adjusted earnings were expected to be between $0.80 and $0.82 per share, surpassing the $0.75 per share in the previous corresponding period.For full year 2026, the company forecast sales growth of 5.5% to 6.5% from $20.07 billion&nbsp;in full year 2025, and adjusted earnings of $3.28 to $3.32 per share, versus $3.06 per share last year.The company now expects to fall short of these ranges because of the cyberattack.<h2 class="st-heading-2">Full Financial Impact Still Uncertain</h2>On Tuesday, Boston Scientific said its distribution network has been substantially restored, with major centers processing and shipping orders at or above normal levels. Sterilization facilities are also operational, while manufacturing has resumed across most global facilities. However, it said the timeline for a full operational recovery is not yet known.The company expects to recover some impacted revenue as it works through order backlogs, but said the full financial impact remains uncertain. It plans to provide updated guidance for 2026 with its third-quarter results on Oct. 28, 2026.<h2 class="st-heading-2">Retail Debates Support Levels</h2>Retail sentiment surrounding BE on Stocktwits changed to ‘neutral’ from ‘bearish’ over the past 24 hours.One user said the stock is “primed to retest the lows.”<stembedurl>https://stocktwits.com/St0ckt0k101/message/663796014</stembedurl>However, another user believes that the stock may have already bottomed out and will likely climb back over $50 by next week.<stembedurl>https://stocktwits.com/Togdjclecj/message/663789268</stembedurl>The stock has been under heavy selling pressure so far this year, declining more than 52%.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/be-stock-gains-ahead-of-sp-500-inclusion-wall-street-is-bullish/cZtEbgRRJUu">Bloom Energy’s S&amp;P 500 Entry Could Bring A New Wave Of Buyers, Says Clear Street — Projects 20% Upside In BE Stock</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A general view of a Boston Scientific advertisement during a women's college lacrosse game between the Notre Dame Fighting Irish and the Boston College Eagles on March 16, 2024. (Photo by Erica Denhoff/Icon Sportswire via Getty Images)

Boston Scientific expects to provide updated full-year 2026 guidance along with its third-quarter results on Oct. 28, 2026.

$OUST

$BSX

$ALAB

$CRCL

Which of these trending stocks are you most bullish on right now?

Current Price	$45.73
Prev Close	$45.05
Open	$45.76
Dividend Yield	0.00%
50-Day Moving Average	$46.00
Beta	0.57
Avg. Volume	20.92M
PE Ratio	18.27

52-Week High	$105.65
52-Week Low	$41.39
Market Capitalization	$65.29B
EPS (Annual)	$1.94
Price to Book	2.61
Revenue Per Employee	$340,237.29

Feed

News

Sentiment

Earnings

Fundamentals

Info

BSX Fundamentals